Live
FierceBiotechNovartis sticks 2nd deal with molecular glue biotech Orionis, this one worth up to $1.4BLabiotechHow Daiichi Sankyo aims to become a top five oncology player by 2035PharmaVoiceAmid a flurry of biotech deals, China looks to keep innovation at homeCellPrion-based protein self-assembly tunes mutagenesis to enable rapid adaptationEndpoints NewsEthyreal lands $101M to treat both Graves' and thyroid eye diseaseEndpoints NewsSanofi to mull riliprubart’s future after stopping late-stage nerve disease studyFierceBiotechCancer-focused Parabilis’ upsized $670M IPO breaks new for record for biotechsFierceBiotechSanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continueLabiotechBeyond amyloid and dopamine: emerging technologies reshaping neurologyEndpoints NewsParabilis' $670M IPO sets new biotech record, will fund cancer drugeLifeAltered cognitive processes shape tactile perception in autismeLifeCell size modulates ferroptosis susceptibility
BioWorld Jan 5, 2026

Biggest gainers and losers for Dec. 29, 2025-Jan. 2, 2026

Biggest gainers and losers for Dec. 29, 2025-Jan. 2, 2026

Original
Body unavailable. Use the original source.